ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2989

Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus

David Giangreco1, Hervé Devilliers2, Narender Annapureddy1, Joel A. Block3 and Meenakshi Jolly1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, 3Section of Rheumatology, Rush University Medical Center, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, outcome measures and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patient reported outcomes (PRO) are important to understand, educate, manage and follow patients with systemic lupus erythematosus (SLE).  Lupus Impact Tracker (LIT) is a ten-item tool developed to facilitate patient-physician communication.  Herein, we present its responsiveness to physician and patient assessed changes in disease status from data obtained during routine SLE patient care visits. 

Methods: Longitudinal data on LupusPRO, physician assessed disease activity assessment, and patient reported changes in SLE health status was collected during 182 SLE patient routine clinical care visits.  LIT score was derived from PRO data.  Disease activity assessments used as anchors for testing responsiveness were the SLEDAI physician global assessment (PGA), Total SELENA-SLEDAI score, SELENA-Flare Index (SFI), and Patient reported changes in SLE health status.  Cut-offs used to determine change in disease activity were as follows: PGA (change of 0.3), Total SELENA-SLEDAI (change of 4), SFI (remitting, stable, and flaring) and Patient reported changed in SLE health status (-7 to 7).  For patient reported change in SLE health status, we categorized -2 to 2 as unchanged, -3 to -7 as worsening and 3 to 7 as improvement.  Mixed model regression analysis was used to compare changes in LIT against disease activity and patient reported changes in SLE health status anchors.

Results: There were 658 visit data available for 182 SLE patients.  Consecutive visits were 2-5 months apart with a median number of visits per patient of 7.  PGA was available for 630 visits; Total SLEDAI was available for 249 visits; SFI was available for 610 visits ; Patient reported change in SLE health status was available for 449 visits.  Mean (SD) age and SELENA-SLEDAI were 43.5 (13.2) years and 6.4 (7.3), respectively.  PGA changed significantly for 269 visit data (increased in 125, decreased in 144) while 361 visit data had unchanged PGA.  Total SELENA-SLEDAI changed significantly among 66 visits (29 increased, 37 decreased) and remained stable among 183 visits.  Significant changes in SFI were observed in 149 visit data (80 remitting, 69 flaring) while 461 visit data was unchanged.  Patient reported change in SLE health status changed significantly for 221 (150 improved, 71 worsened) and remained stable for 228 visits.  LIT scores responded significantly and in the appropriate direction for changes in PGA (p<0.05), Total SLEDAI (p=0.01), and SFI (p<0.05) and patient reported changes in SLE health status (p=0.001).

Conclusion: LIT is responsive to physician- and patient-assessed changes in disease status in SLE.  In addition to being used in clinical trials, LIT is an effective tool that may be used by patients and physicians in facilitating communication and tracking disease impact in SLE.


Disclosure:

D. Giangreco,
None;

H. Devilliers,
None;

N. Annapureddy,
None;

J. A. Block,
None;

M. Jolly,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-impact-tracker-is-responsive-to-changes-in-disease-activity-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology